Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease
Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal’s website and are available to subscribers.

Read more on News-Medical-Net